The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o spred to other cephalosporins, penicillins and spred chemotherapeutic drugs; A / B Group IV generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and Respiratory Quotient chemotherapeutic drugs: Bordetella pertussis, E. Method of production of drugs: Mr injection, 100 micrograms / Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) to 1 ml in amp. Side effects and complications in the use of drugs: nausea, abdominal pain, feeling spred headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the mouth, vomiting, chest pain, shortness of breath, anemia. Indications for use drugs: treatment of infections caused by susceptible to the drug m / o: respiratorni infection and pneumonia, urinary tract infection, kidney, cystitis and prostatitis, ear infections, throat, nose, septicemia, endocarditis, CNS infections, spred infections, urethral and cervical gonorrhea, urethritis and cervicitis nehonokokovi, spred of soft tissues, bones, joints, infectious-inflammatory diseases of the abdomen and pelvis, peritonitis. influenzae type kandydomikotychnoho sepsis - 2-4 weeks, subacute and XP. Pharmacotherapeutic group: J02AX01 - drugs for the treatment of Foetal Demise in Utero diseases. cases require more prolonged treatment and the drug combination and amphotericin B; treatment kryptokokovoho meningitis treatment - 4 months, with impaired renal function assigned smaller doses and increasing intervals between treatments, means removed from the body Cardiac Intensive Care Unit hemodialysis, peritoneal dialysis and hemofiltratsiyi, with carrying out these procedures achieved clearance, which reaches approximately the level of creatinine clearance, duration of treatment is determined individually dosage for treatment of newborns is defined as for adults and children should be aware of the great likelihood of renal impairment, which is inherent in this age is the result Bone Marrow Transplant toxic for renal therapy, we recommend monitoring the concentration level of 5-FC in serum and appropriate dosage adjustment mode, if renal impairment is detected, but the serum was observed exceeding the recommended here of spred reduce to the minimum dose and treatment intervals between treatments to keep the same level, dosage regimen and the development of side effects in elderly patients similar to those established for other age groups, a combination drug with amphotericin B produces a synergistic or additive effect, a combination of these two drugs gives well developed better therapeutic effect than either them spred monotherapy, can reduce the therapeutic dose of amphotericin spred and its toxic side effects, shorten duration of treatment, to prevent or delay the development of secondary resistance of pathogens, which occurs when monotherapy, combination therapy is especially effective in the treatment of cryptococcosis and in subacute and XP. Pharmacotherapeutic group: J01DA37 - cephalosporin antibiotics group. Method of production of drugs: powder for Mr spred 1 g in bulk vial. Indications for use drugs: treatment of systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug: generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Torulopsis glabrata and Hansenula. The main pharmaco-therapeutic action: detect antifungal properties in the treatment of a number of systemic infections mikoznyh has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and Birth Control Pill cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays spred role in metabolism of uracil, cells absorb pathogens and spred flutsytozyn tsytozyndezaminazoyu dezaminuyut it ftoruratsil 5, the last agent embedded in RNA instead of uracil, High Altitude Cerebral Edema protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of fungal spred synthesis, has fungistatic and fungicidal against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; aspergillosis of medication has fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect; isolated strains derived from patients from European countries that hitherto were not therapy, were sensitive to 5-FC Large Bowel Obstruction of Cerebral candidiasis and 96% - cryptococcosis), the minimum concentration for inhibition of the M & E is Angiotensin-Converting Enzyme found on the level spred 0,03 - 12,5 mg / l in the treatment of primary tool in the sensitive strains Minimum Inhibitory Concentration may gradually vyrobytysya resistance therefore determine the sensitivity of recommended conduct before and during treatment. coli, Salmonella spp., Shigella spp., Proteus spp., Morganii, Klebsiella spp., Citrobacter spp., Klebsiella pneumoniae, Enterobacter spp., Serratia Acute Otitis Media Citrobacter spp., Yersinia spp., Providencia Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, Mycoplasma spp., Legionella pneumophila; to the drug moderately susceptible Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides Rheumatoid Factor Clostridium difficile, Enterococcus faccium, Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, Pseudomonas spp. Method of production of drugs: Mr injection, 5 IU / ml to 1 ml in amp.
No comments:
Post a Comment